<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082119</url>
  </required_header>
  <id_info>
    <org_study_id>1138</org_study_id>
    <nct_id>NCT02082119</nct_id>
  </id_info>
  <brief_title>Hypofractionated IMRT With Temozolomide for HGG</brief_title>
  <official_title>Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy,
      concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.

      Primary endpoint: progression free survival (PFS), Overall Survival (OS) and Toxicity.

      Secondary endpoint: to evaluate Quality of life (QoL) of patients after surgery, concomitant
      chemoradiotherapy and adjuvant chemotherapy through neuropsychological examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a study of a hypofractionated intensity modulated radiation therapy (IMRT), using
      VMAT RapidArc approach. The potential advantage of this approach is to deliver a more
      selective irradiation to tumor's target with reducing dose to normal brain and to allow to
      deliver a higher dose, optimizing the therapeutic window
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS), Overall Survival (OS) and Toxicity</measure>
    <time_frame>time of enrollment of two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) of patients after surgery, concomitant chemo-radiotherapy and adjuvant chemotherapy</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>High Grade Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated IMRT</intervention_name>
    <description>Hypofractionated IMRT</description>
    <arm_group_label>High Grade Glioma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Karnosky performance status (KPS) ≥60

          -  Patients aged &gt;70 years with KPS ≥80

          -  Histopathologically confirmed of HGG

          -  Estimated survival ≥ 3 months.

          -  Multifocal tumor

          -  Normal liver, Kidney and bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Prior radiation therapy

          -  KPS ≤ 60

          -  Age &gt; 70 years and KPS &lt; 70

          -  Other primary cancer

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Study Director</role>
    <affiliation>Humanitas Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.</citation>
    <PMID>22483738</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>Istituto Clinico Humanitas</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 13, 2016</submitted>
    <returned>February 3, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

